Cutia Therapeutics Presents Acne Drug's Phase III Clinical Trial Results at Asian Dermatology Congress

Cutia Therapeutics (HKG:2487) presented the results of the phase III clinical trial of its topical 4% minocycline foam for treating non-nodular moderate-to-severe acne vulgaris at the 13th Asian Derma

MT NewswiresMay 30 22:38 ET

Cordi-B (02487): CU-10201 (4% minocycline foam for external use) Chinese phase III clinical trial results released at the 13th ADC Annual Meeting

Cordi-B (02487) announced that the Group treats non-nodular moderate to severe acne vulgaris product CU-102...

Zhitong FinanceMay 30 18:13 ET

Cutia Therapeutics Obtains Clinical Trial Approval in China for Dermatitis Drug

Cutia Therapeutics' (HKG:2487) investigational new drug application to conduct a Phase 1 clinical trial of CU-10101 in China has been approved by the Center for Drug Evaluation of China's National Med

MT NewswiresMay 30 01:39 ET

[Hong Kong Stock Connect] Kodi (02487): Clinical trial application for a new drug to treat atopic dermatitis approved to conduct phase I clinical trials in China

Jinwu Financial News | Kedi (02487) announced that CU-10101's new drug clinical trial application for the treatment of mild to moderate atopic dermatitis has been approved by the Drug Evaluation Center of the State Drug Administration to conduct phase I clinical trials in China. CU-10101 is a non-hormonal, small molecule drug suitable for the treatment of mild to moderate atopic dermatitis. Treatment options for atopic dermatitis are limited, mainly including corticosteroids, calcineurin inhibitors, systemic immunosuppressants, targeted biological agents, and small-molecule drugs.

金吾財訊May 30 00:05 ET

Cordi-B (02487.HK): CU-10101 (novel topical small molecule agent) clinical trial application for the treatment of atopic dermatitis was approved by CDE

On May 30, Gelonghui | Cordi-B (02487.HK) announced that the IND application for CU-10101 has been approved by the CDE and plans to conduct phase I clinical trials in China. CU-10101 is a non-hormonal, small molecule drug suitable for the treatment of mild to moderate atopic dermatitis. Treatment options for atopic dermatitis are limited, mainly including corticosteroids, calcineurin inhibitors, systemic immunosuppressants, targeted biological agents, and small-molecule drugs. Topical corticosteroid medications are the most commonly prescribed treatment for atopic dermatitis. Most targeted biologics for atopic dermatitis and small

Gelonghui FinanceMay 30 00:02 ET

Cutia Therapeutics' Unit Receives Jiangsu Drug Manufacturing Certificate

Cutia Therapeutics (HKG:2487) said its wholly owned unit Cutia Therapeutics (Wuxi) received a Drug Manufacturing Certificate from the Jiangsu Medical Products Administration, according to a Tuesday fi

MT NewswiresApr 29 23:45 ET